DOCETAXEL by Pfizer is functions. Approved for metastatic breast cancer after failure of prior chemotherapy, metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy, locally advanced and 2 more indications. First approved in 2014.
Drug data last refreshed 4h ago · AI intelligence enriched 3d ago
Docetaxel is a small-molecule taxane chemotherapy agent that stabilizes microtubules by promoting tubulin assembly and inhibiting disassembly, thereby disrupting mitosis and inducing cell death. It is approved for metastatic breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer after failure of prior chemotherapy. Docetaxel represents a foundational cytotoxic backbone in solid tumor oncology.
Docetaxel is at peak maturity with moderate competitive pressure (30/100), suggesting stable but not expanding commercial teams; most hiring activity is likely in field maintenance and cost-containment roles.
functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, which results in the…
Worked on DOCETAXEL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
Docetaxel roles are concentrated in commercial execution and market access rather than innovation; this product suits professionals focused on managed care negotiation, field excellence, and market share defense in a mature oncology space. Positions on this brand offer stable but narrowing career development, with upside tied to emerging combination therapies or geographic expansion.